1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,

Slides:

Advertisements

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Advertisements

Purpose (You may click to go to the specific section or proceed through the presentation) Briefly review West Nile virus (WNV) ecology and epidemiology.

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

A PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION TESTING ON POOLED PLASMA VS. INDIVIDUAL DONATION HIV P24 TESTING.

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

Dengue Virus and Its Risk to the U.S. Blood Supply

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,

Black Bugs Blood: West Nile Virus & the Blood Supply Infectious Transfusion Risks, Screening Blood donations for WNV and other icky things Jed Gorlin,

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;

Tarrant County Public Health North Texas Regional Laboratory Six Years of West Nile Virus in Tarrant County, Texas Guy C. Dixon, Ph.D.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

BioLife Plasma Services Experience with HBV NAT Testing

HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.

West Nile Virus Jo Hofmann, MD State Epidemiologist for Communicable Disease Washington State Department of Health Focus on clinical aspects of human infection.

REAL-TIME SCREENING FOR WEST NILE VIRUS (WNV) OF ORGAN DONORS Claudia Chinchilla, CLSpMB 1, Jaime Siriban, CLS 1, Dem Brucal, CLS 1, James Schellenberg,

Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

Standardization – CBER update June 12, 2007 XX SoGAT Indira Hewlett, Ph.D. Chief, Lab. of Molecular Virology DETTD/CBER/FDA.

Maria Rios, Ph.D. CBER/FDA Blood Products Advisory Committee May 1st, WNV Epidemiology & FDA’s Recommendations on the Use of NAT to Reduce the.

Background Recruitment strategies for organ and tissue donors are different, and although some organ donors do eventually become tissue donors, organ donors.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

Detection of Dengue Virus RNA in Blood Donors from Honduras and Brazil with a Prototype Transcription-Mediated Amplification Assay.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

Qualification Panels for West Nile Virus RNA Tests Mark Manak, Ph.D. Boston Biomedica, Inc. West Bridgewater, MA SoGAT Langen, Germany July 3, 2003.

Real and perceived problems with Nucleic Acid Testing for organ and tissue donors 5 years experience Claudia Chinchilla, MB(ASCP)1, Dem Brucal, CLS1, James.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

Overview of Data on Blood Donor Testing and Plan for Studies to Characterize Rates and Consequences of Transfusion Transmission of Dengue Virus Michael.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

E WNV Confirmation in US Blood Donors and Data in Support of WNV ID-NAT Triggers Susan L. Stramer, Ph.D. Blood Products Advisory Committee.

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

SynTura: A New Ribonuclease Resistant Viral RNA Control Material Ralf Schönbrunner, Ph.D. SoGAT XXI Brussels, Belgium May 28, 2009.

E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.

Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.

E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.

Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.

Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,

DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.

Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVI, Langen 3 rd July 2003 Immediate Parvo B19 NAT testing of pooled donor samples: logistics and.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.

Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

How dangerous are Donor Travels?

TRANSFUSION: Blood donation and preparation of blood components

Results of Recent EQA Panels for Blood Borne Viruses

Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)

Update on CBER HIV-1 Subtype panel

Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K

1st International Standard for HIV-1 RNA NIBSC Code 97/656

SoGAT meeting XXI May (2009), Brussels, Belgium

Presentation transcript:

1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated, San Diego, CA USA SoGAT July 3, 2003 Procleix® is a registered trademark of Chiron Corporation

2 Procleix WNV Assay Based on Transcription Mediated Amplification (TMA) Uses same instrument platform as Gen-Probe’s licensed NAT blood screening assay –Procleix Semi-automated System currently used with Procleix HIV-1/HCV Assay TECANTarget Capture System (TCS)Luminometer

3 Specificity of the Procleix WNV Assay 1,680 normal blood donations were tested at Gen-Probe –99.8% initial specificity; 100% resolved specificity –over 40,000 archived samples from 2002 high risk populations have been tested by American Red Cross (S. Stramer) No cross reactivity to other blood borne viruses –Testing included HTLV, HIV-1/-2, HCV, HBV, HGV, Rubella, HAV, CMV, EBV, HCV, Parvo B19 Assay designed to specifically detect West Nile virus: –No cross reactivity to other flaviviruses: Dengue (1-4), Yellow Fever Virus, and St. Louis Encephalitis virus ; weak cross reactivity to Murray Valley Encephalitis virus –Detects Kunjin virus (Australian subtype of West Nile virus)

4 Analytical Sensitivity *virus quantified by BBI TaqMan Assay (BBI Diagnostics, West Bridgewater, MA). Based on data from Procleix WNV Assay kit lot manufactured at 2 million test scale **Quantitation for this panel is probably not accurate Probit Analysis (results from BBI panels): Lineage 1: 95% detection at 4 to 14 copies/mL Lineage 2: 95% detection at 4 to 8 copies/mL

5 Samples from CDC WNV Transfusion Transmission Case Investigations (2002) Positive Results from testing 383 blinded samples sent to Gen-Probe from the American Red Cross All donations implicated in transfusion transmission were detected at 1:16 dilution with TMA

6 Nationwide WNV Blood Screening in the United States, 2003 Testing using the Procleix WNV Assay started on June 19 –Implemented nationwide on July 1 –Test development which normally takes 2 to 3 years was condensed into less than 9 months. –Procleix WNV Assay is being used to test over 80% of the US blood supply Most donations are being tested in pools of 16 (some sites are testing individual donations) –reactive pools will be resolved to individual donation Testing will reduce the risk of WNV transfusion transmission –will provide real time surveillance of human WNV activity in North America

7 Acknowledgements Gen-Probe WNV Assay Development Team –(Front to back, left to right) Mike Shih, Josh Cary, Geoffrey Dennis, Janice Cline, Martha Alden, Wen Wu, Mackenzie Lewis, Michelle Cass, Amy Broulik, Jeff Linnen, Stephanie Miller National Heart, Lung, and Blood Institute (NHLBI) for partial funding Susan Stramer, American Red Cross Chiron Corporation